Marjorie Taylor Greene and other conservative commentators have claimed that Moderna is developing a hantavirus mRNA vaccine.
This development renewed investor confidence in Moderna’s mRNA pipeline, even as a cluster of hantavirus cases emerged on a ...
The stock has rapidly outpaced the broader market, but the long-term implications of the hantavirus are unclear.
These efforts are early-stage and ongoing and reflect Moderna’s broader responsibility to develop countermeasures against ...
Moderna Inc MRNA shares are trading higher Friday morning as traders react to peer reviewed Phase 3 flu-vaccine data. Here’s ...
After a large trial showed stronger protection, regulators are weighing whether Moderna’s mRNA vaccine could become a U.S.
Moderna reported positive Phase 3 results for its mRNA seasonal influenza vaccine candidate, mRNA-1010, showing stronger ...
Moderna’s new mRNA based seasonal flu vaccine is more effective than traditional flu shots at preventing flu, a late stage ...
Regulatory filings are under review in the U.S., Europe, Canada and Australia, with potential approvals expected to ...
An mRNA-based flu shot could make a huge difference in flu prevention, allowing scientists to pick a better strain match.
The findings arrive after a swirl of regulatory uncertainty surrounding the trivalent (three-strain) vaccine, mRNA-1010.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results